SAN DIEGO--(BUSINESS WIRE)--Pathway Genomics Corporation, a genetic testing laboratory specializing in nutrition and exercise response, inherited disease, prescription drug response and health condition risks, has established a world-leading scientific advisory board.
Among the board members are Arne Astrup, M.D., Ph.D., head of the department of human nutrition at the University of Copenhagen, Claude Bouchard, Ph.D., executive director of the Pennington Biomedical Research Center, and Ken Fujioka, M.D., director of the Scripps Nutrition and Metabolic Research Center – all known for their breakthrough discoveries in obesity research, nutrition and weight management clinical trials.
“Collaborating with outside experts of this caliber is vital for Pathway to bring the latest scientific and technological advancements and methods in genomic and translational medicine to health care providers and their patients,” said Michael Nova, M.D., Pathway Genomics’ chief medical officer. “Pathway’s mission is to educate and empower people by providing actionable genetic information – our scientific advisory board is an essential part of that effort.”
Pathway’s scientific advisory board consists of 10 leaders in various fields including behavioral genetics, bioinformatics, biostatistics, endocrinology, human epigenetics, metabolism, nutrigenomics, nutrition, obesity and exercise genetics, oncology, and weight management. To view the company’s full scientific advisory board, visit www.pathway.com/sab.
About Pathway Genomics
Pathway Genomics owns and operates an on-site genetic testing laboratory that is accredited by the College of American Pathologists (CAP), accredited in accordance with the U.S. Health and Human Services’ Clinical Laboratory Improvement Amendments (CLIA) of 1988, and licensed by the state of California. The company uses customized and scientifically validated technologies to generate personalized reports, which address a variety of medical issues, including an individual’s carrier status for recessive genetic conditions, food metabolism and exercise response, prescription drug response, and propensity to develop certain diseases, such as heart disease, type 2 diabetes, and cancer. For more information about Pathway Genomics, visit www.pathway.com.